Insys Therapeutics (INSY) Misses Q2 EPS by 17c

Insys Therapeutics (NASDAQ: INSY) reported Q2 Adj. EPS of ($0.33), $0.17 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $38 million versus the consensus estimate of $25.91 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c